NEUROREADINESS
Blood-Based Diagnostics and Enzyme -Targeted Therapy for Cognitive Health

“Protecting those who’ve led the way - readiness starts with the mind.”

CATEGORY

Neurodiagnostics • Cognitive Health • Aging Warfighter Support • Blood-Based Biomarkers

OPERATIONAL RELEVANCE

Cognitive decline affects judgment, reaction time, and mission readiness. As military personnel age or experience high-stress environments and neurotrauma, maintaining neurovascular health becomes essential. This technology is a minimally invasive diagnostic and therapeutic platform that enables early detection and intervention for neurodegenerative risk and cognitive impairment. It may also be relevant in TBI-related inflammation.

TECHNOLOGY SUMMARY

This innovation measures plasma levels of two H₂S-generating enzymes—CBS and CSE—to assess neurovascular function and cognitive health. The ELISA-based assay provides a low-cost, scalable blood test for screening and disease staging. These same biological pathways are under investigation in neurotrauma and TBI, offering dual application potential. Targeted modulation of these enzymes may enable early-stage neuroprotection and cognitive support interventions.

MILITARY-ALIGNED BENEFITS

• Enables early identification of neurovascular dysfunction and cognitive risk
• Relevant to long-term health monitoring of aging service members and veterans
• May support neurotrauma, TBI, and PTSD evaluations via shared inflammation pathways
• Ideal for use in DoD/VA screening and wellness programs
• Scalable, cost-effective, and non-invasive—suitable for clinical and field settings

USE SCENARIOS

• VA and military health systems for routine cognitive and neurological screening
• Neurotrauma and TBI recovery evaluations
• Diagnostic tool for SBIR/STTR-funded research in cognitive health
• Screening for neurovascular integrity in high-stress occupations
• Companion diagnostic for neuroprotective or performance-support therapeutics

Scientific Highlights

• Biomarker Signature: Elevated CBS (+2x), reduced CSE (−20%) in impaired patients
• Diagnostic: ELISA-based assay with scalable and stable design
• Therapeutic Potential: CBS inhibition and CSE augmentation reduce inflammation
• TBI Link: Enzyme pathways tied to neuroinflammatory responses
• Clinical Correlation: Biomarkers align with known markers of cognitive decline

TECHNOLOGY READINESS & IP

• Technology ID: LSUHSC-S-2023-020
• TRL: 3 – Early-stage validation in human samples
• Patent Status: PCT/US2024/054389 (Patent Pending)

Collaboration Opportunity

We are seeking partners to:

• Validate use in veteran and active-duty populations
• Advance therapeutic approaches targeting CBS/CSE enzymes
• Integrate into cognitive resilience programs
• Co-develop technology under SBIR, STTR, or CRADA programs